The early days of peer review: five insights from historic reports
nature.com
nature.com
How many papers are actually replicable? How many are the result of citation cartels or outright fraud?
I remember Shriram Krishnamurthi talking about artifact evaluation in papers [1]. I think that's a great initiative that should be adopted by all fields of science.
--
Paraphrasing Wikipedia [2] [3].
"Robert Maxwell, described as a "British media proprietor, politician, and fraudster," founded Pergamon Press, an Oxford-based publishing house specializing in scientific and medical books and journals. Known for his flamboyant lifestyle, ultimately embezzled hundreds of millions from his own companies.
Pergamon (originally Butterworth-Springer), was established in 1948 to bring "Springer’s know-how and aggressive publishing techniques in science" to Britain. Today, Pergamon Press operates as an imprint of Elsevier."
I had no idea. Beyond wild!
--
1: Not to be confused with James Clerk Maxwell (1831–1879), creator of "Maxwell's equations".
See this encyclopedia entry for a short summary of the issues by a historian: https://ethos.lps.library.cmu.edu/article/id/38/
Because you need to draw the line somewhere reasonable.
Otherwise, why don't we take your logic one step further and say an aluminum sheet is an earlier form of the Boeing 747 ?
The difference between the Wright Brother's plane and a Boeing 747 is simply too enormous to be a logical "earlier form".
The only thing the two share are the fundamental physics of aerodynamics. And even then, we are only talking the sort of shared aerodynamics you'll learn about at an aerospace museum on a school trip when you get to put a piece of cardboard in a wind tunnel.
Its a bit like saying a donkey is an earlier form of a car. Well, sure, people used to use donkeys extensively for transport. But I think most people would agree calling it an earlier form of a car is pushing it.
In the same way, cats are a smaller form of a mammal, and giraffes are a larger form of a mammal. That doesn't make cats a smaller form of a giraffe.
From dictionary.com: "a tall, long-necked, spotted ruminant, Giraffa camelopardalis, of Africa: the tallest living quadruped animal."
A cat does not fit that definition, no matter how hard you squint.
As if it wasn’t enough to essentially invent the field of theoretical computer science and save possibly millions of lives in the war, he then decided in 1952 to casually publish in the field of biology.
He had no formal training in biology, and when peer reviewers including the grandson of Charles Darwin commented on his paper “Turing seems to have ignored both sets of comments” lol.
Nevertheless the paper turned out to be groundbreaking and is still considered relevant today. Total badass.
Science translates observation into abstraction. (That's a big leap. And yes, one could make one's own observation. But nobody has the time for that.)
But is it a good abstraction? (And then we have all these methods for ensuring that.)
Also, why this implicit preference for abstraction? (Yes there's an upside. But consider the downside.)
Sight, sound, taste, etc are not that.
(I suppose even words are not necessarily symbols. I mean, if you don't assign meaning, if you don't interpret it that way, then a word is just a unique pattern of squiggles)
We train grad students to do reviews by having them do reviews under close supervision, yes. You say it like it’s a bad thing.
Screw that. If you want me to put in the effort to read k pages of your conference or journal paper you better be prepared to read k papers of my review.
It matters outside of academics because NIH funding distributions are linked to exclusive patents for pharmaceutical corporations, which represent a massive public subsidy for the pharma sector. This system also accounts for much of the price inflation in the medical drug markets in the USA, and a lack of research into medical uses of out-of-patent (cheap) drugs. See for example:
https://medicalxpress.com/news/2023-07-nih-spent-950m-basic-...
> "The article in PLOS ONE titled, "NIH funding for patents that contribute to market exclusivity of drugs approved 2010–2019 and the public interest protections of Bayh-Dole," is the first to look broadly at the NIH funding for the basic and applied research related to new drug approvals and the proportion of this research that leads to patents that give manufacturers market exclusivity."